Clinical observation and management of COVID-19 patients
Three leading infectious disease experts in China were invited to share their bedside observations in the management of COVID-19 patients. Professor Taisheng Li was sent to Wuhan to provide frontline medical care. He depicts the clinical course of SARS-CoV-2 infection. Furthermore, he observes the s...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2020.1741327 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850150278006833152 |
|---|---|
| author | Taisheng Li Hongzhou Lu Wenhong Zhang |
| author_facet | Taisheng Li Hongzhou Lu Wenhong Zhang |
| author_sort | Taisheng Li |
| collection | DOAJ |
| description | Three leading infectious disease experts in China were invited to share their bedside observations in the management of COVID-19 patients. Professor Taisheng Li was sent to Wuhan to provide frontline medical care. He depicts the clinical course of SARS-CoV-2 infection. Furthermore, he observes the significant abnormality of coagulation function and proposes that the early intravenous immunoglobulin and low molecular weight heparin anticoagulation therapy are very important. Professor Hongzhou Lu, a leader in China to try various anti-viral drugs, expresses concern on the quality of the ongoing clinical trials as most trials are small in scale and repetitive in nature, and emphasizes the importance of the quick publication of clinical trial results. Regarding the traditional Chinese medicine, Professor Lu suggests to develop a creative evaluation system because of the complicated chemical compositions. Professor Wenhong Zhang is responsible for Shanghai's overall clinical management of the COVID-19 cases. He introduces the team approach to manage COVID-19 patients. For severe or critically ill patients, in addition to the respiratory supportive treatment, timely multiorgan evaluation and treatment is very crucial. The medical decisions and interventions are carefully tailored to the unique characteristics of each patient. |
| format | Article |
| id | doaj-art-31ff3d2df24e46adb4efac633ecffa52 |
| institution | OA Journals |
| issn | 2222-1751 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-31ff3d2df24e46adb4efac633ecffa522025-08-20T02:26:36ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512020-01-019168769010.1080/22221751.2020.1741327Clinical observation and management of COVID-19 patientsTaisheng Li0Hongzhou Lu1Wenhong Zhang2Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People’s Republic of ChinaShanghai Public Health Clinical Center, Shanghai, People’s Republic of ChinaDepartment of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaThree leading infectious disease experts in China were invited to share their bedside observations in the management of COVID-19 patients. Professor Taisheng Li was sent to Wuhan to provide frontline medical care. He depicts the clinical course of SARS-CoV-2 infection. Furthermore, he observes the significant abnormality of coagulation function and proposes that the early intravenous immunoglobulin and low molecular weight heparin anticoagulation therapy are very important. Professor Hongzhou Lu, a leader in China to try various anti-viral drugs, expresses concern on the quality of the ongoing clinical trials as most trials are small in scale and repetitive in nature, and emphasizes the importance of the quick publication of clinical trial results. Regarding the traditional Chinese medicine, Professor Lu suggests to develop a creative evaluation system because of the complicated chemical compositions. Professor Wenhong Zhang is responsible for Shanghai's overall clinical management of the COVID-19 cases. He introduces the team approach to manage COVID-19 patients. For severe or critically ill patients, in addition to the respiratory supportive treatment, timely multiorgan evaluation and treatment is very crucial. The medical decisions and interventions are carefully tailored to the unique characteristics of each patient.https://www.tandfonline.com/doi/10.1080/22221751.2020.1741327Clinical managementantiviral drugscoronavirusSARSSARS-CoV-2 |
| spellingShingle | Taisheng Li Hongzhou Lu Wenhong Zhang Clinical observation and management of COVID-19 patients Emerging Microbes and Infections Clinical management antiviral drugs coronavirus SARS SARS-CoV-2 |
| title | Clinical observation and management of COVID-19 patients |
| title_full | Clinical observation and management of COVID-19 patients |
| title_fullStr | Clinical observation and management of COVID-19 patients |
| title_full_unstemmed | Clinical observation and management of COVID-19 patients |
| title_short | Clinical observation and management of COVID-19 patients |
| title_sort | clinical observation and management of covid 19 patients |
| topic | Clinical management antiviral drugs coronavirus SARS SARS-CoV-2 |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2020.1741327 |
| work_keys_str_mv | AT taishengli clinicalobservationandmanagementofcovid19patients AT hongzhoulu clinicalobservationandmanagementofcovid19patients AT wenhongzhang clinicalobservationandmanagementofcovid19patients |